Pediatric Hepatitis A Medication
- Author: Nicholas John Bennett, MB, BCh, PhD; Chief Editor: Russell W Steele, MD more...
Medication Summary
No specific treatment for hepatitis A virus (HAV) exists. Accordingly, treatment is supportive rather than directly curative. Agents used include analgesics, antiemetics, vaccines, and immunoglobulins. Prevention (either before or after exposure to HAV) is important.
Long-term studies indicate that seropositivity conferred by hepatitis A vaccine lasts at least ten years in children under the age of 2 years, although titers are somewhat lower in those children whose mothers were hepatitive A-positive by serology, presumably through interference with the vaccine. The significance of these lower titers is uncertain.[14]
Vaccines
Class Summary
Vaccination is indicated for primary immunization to prevent hepatitis A. It is also used for postexposure prophylaxis, either alone or in conjunction with immune globulin (IG).
Hepatitis A vaccine inactivated (Havrix, Vaqta)
For active immunization against disease caused by hepatitis A virus (HAV). Complete primary immunization at least 2 wk prior to expected exposure to HAV. Primary immunization series consists of 2 doses.
Analgesic Agents
Class Summary
Pain control is essential to quality patient care. Acetaminophen is useful for pain and/or fever.
Acetaminophen (Tylenol, Children's Nortemp, FeverAll)
Acetaminophen reduces fever by acting directly on hypothalamic heat-regulating centers, thereby increasing dissipation of body heat via vasodilation and sweating. It relieves mild to moderate pain.
Antiemetics
Class Summary
Antiemetic agents are used to treat nausea and vomiting.
Metoclopramide (Reglan, Metozolv)
Antiemetic agents are used to treat nausea and vomiting.
Immune Globulins
Class Summary
These are purified preparations of gamma globulin. They are derived from large pools of human plasma and are composed of 4 subclasses of antibodies, approximating the distribution of human serum. They are used for postexposure prophylaxis or when inadequate time is available for immunization to be effective before potential exposure.
Immune globulin IM (Gamunex, Octagam, Gammaplex)
Immune globulin IM neutralizes circulating virus. It is effective for pre-exposure protection and for post-exposure protection when administered within 14 days of exposure. It should be used in place of vaccination in those children too young (< 1 y) for vaccination when the child is traveling to an endemic area.
Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. Dec 7 1973;182(116):1026-8. [Medline].
Todd EC, Greig JD, Bartleson CA, Michaels BS. Outbreaks where food workers have been implicated in the spread of foodborne disease. Part 4. Infective doses and pathogen carriage. J Food Prot. Nov 2008;71(11):2339-73. [Medline].
Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ. Mar 21 2008;57(2):1-24. [Medline]. [Full Text].
Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. Jul 13 2005;294(2):194-201. [Medline].
Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007. Arch Intern Med. Nov 8 2010;170(20):1811-8. [Medline].
CDC. Notice to readers: FDA approval of Havrix (hepatitis A vaccine, inactivated) for persons aged 1-18 years. MMWR. December 9, 2005;54(48):1235-1236. [Full Text].
CDC. Notice to readers: FDA approval of VAQTA (hepatitis A vaccine, inactivated) for children aged >1 year. MMWR. October 14, 2005;54(40):1026. [Full Text].
Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. May 19 2006;55:1-23. [Medline]. [Full Text].
Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. Oct 25 2007;357(17):1685-94. [Medline]. [Full Text].
[Guideline] Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. Oct 19 2007;56(41):1080-4. [Medline].
AAP. Hepatitis A vaccine recommendations. Pediatrics. Jul 2007;120(1):189-99. [Medline].
Ahmed M, Munshi SU, Nessa A, Ullah MS, Tabassum S, Islam MN. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy. Indian J Med Microbiol. Jan-Mar 2009;27(1):48-50. [Medline].
Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. Dec 15 2008;198(12):1776-82. [Medline].
Sharapov UM, Bulkow LR, Negus SE, Spradling PR, Homan C, Drobeniuc J, et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology. Feb 28 2012;[Medline].
Print
